> If the cost of insulin is capped on its own, insulin will be more likely to jump in front of SGLT2 inhibitors and GLP-1 receptor agonists in treatment plans. That will mean more disease, more disability, and more death from diabetes.
I doubt this is a sensible calculation. Sure, in some way different medication for the same indication do compete with each other, but the price of insulin does not inhibit the lack of success of alternatives. That would primarily be the ones that do the prescriptions in the first place.
